Alimera Sciences (NASDAQ: ALIM) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

37.2% of Alimera Sciences shares are owned by institutional investors. Comparatively, 97.5% of BioMarin Pharmaceutical shares are owned by institutional investors. 14.7% of Alimera Sciences shares are owned by insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Alimera Sciences and BioMarin Pharmaceutical’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Alimera Sciences $35.96 million 2.63 -$16.78 million ($0.39) -3.51
BioMarin Pharmaceutical $1.20 billion 13.87 -$106.70 million ($1.09) -87.09

Alimera Sciences has higher revenue, but lower earnings than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Alimera Sciences and BioMarin Pharmaceutical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alimera Sciences 0 0 3 0 3.00
BioMarin Pharmaceutical 0 6 16 0 2.73

Alimera Sciences presently has a consensus price target of $4.00, indicating a potential upside of 191.97%. BioMarin Pharmaceutical has a consensus price target of $112.00, indicating a potential upside of 17.98%. Given Alimera Sciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Alimera Sciences is more favorable than BioMarin Pharmaceutical.

Volatility and Risk

Alimera Sciences has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.

Profitability

This table compares Alimera Sciences and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alimera Sciences -68.58% N/A -36.39%
BioMarin Pharmaceutical -15.54% -5.77% -4.00%

Summary

Alimera Sciences beats BioMarin Pharmaceutical on 7 of the 13 factors compared between the two stocks.

About Alimera Sciences

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.